Schanz, Julie

[["dc.bibliographiccitation.firstpage","820"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","829"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Tuechler, Heinz"],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","Mallo, Mar"],["dc.contributor.author","Luno, Elisa"],["dc.contributor.author","Cervera, Jose"],["dc.contributor.author","Granada, Isabel"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Ohyashiki, Kazuma"],["dc.contributor.author","Steidl, Christian"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Noesslinger, Thomas"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Krieger, Otto"],["dc.contributor.author","Garcia-Manero, Guillermo"],["dc.contributor.author","Faderl, Stefan"],["dc.contributor.author","Pierce, Sherry"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:12:21Z"],["dc.date.available","2018-11-07T09:12:21Z"],["dc.date.issued","2012"],["dc.description.abstract","Purpose The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of the International Prognostic Scoring System (IPSS) in 1997, knowledge concerning the prognostic impact of abnormalities has increased substantially. The present study proposes a new and comprehensive cytogenetic scoring system based on an international data collection of 2,902 patients. Patients and Methods Patients were included from the German-Austrian MDS Study Group (n = 1,193), the International MDS Risk Analysis Workshop (n = 816), the Spanish Hematological Cytogenetics Working Group (n = 849), and the International Working Group on MDS Cytogenetics (n = 44) databases. Patients with primary MDS and oligoblastic acute myeloid leukemia (AML) after MDS treated with supportive care only were evaluated for overall survival (OS) and AML evolution. Internal validation by bootstrap analysis and external validation in an independent patient cohort were performed to confirm the results. Results In total, 19 cytogenetic categories were defined, providing clear prognostic classification in 91% of all patients. The abnormalities were classified into five prognostic subgroups (P < .001): very good (median OS, 61 months; hazard ratio [HR], 0.5; n = 81); good (49 months; HR, 1.0 [reference category]; n = 1,809); intermediate (26 months; HR, 1.6; n = 529); poor (16 months; HR, 2.6; n = 148); and very poor (6 months; HR, 4.2; n = 187). The internal and external validations confirmed the results of the score. Conclusion In conclusion, these data should contribute to the ongoing efforts to update the IPSS by refining the cytogenetic risk categories. J Clin Oncol 30: 820-829. (C) 2012 by American Society of Clinical Oncology"],["dc.identifier.doi","10.1200/JCO.2011.35.6394"],["dc.identifier.isi","000302626600017"],["dc.identifier.pmid","22331955"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26930"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.relation.issn","0732-183X"],["dc.title","New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","902"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","910"],["dc.bibliographiccitation.volume","128"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Tuechler, Heinz"],["dc.contributor.author","Sanz, Guillermo F."],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Garcia-Manero, Guillermo"],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Bowen, David"],["dc.contributor.author","Fenaux, Pierre"],["dc.contributor.author","Dreyfus, Francois"],["dc.contributor.author","Kantarjian, Hagop M."],["dc.contributor.author","Kuendgen, Andrea"],["dc.contributor.author","Malcovati, Luca"],["dc.contributor.author","Cazzola, Mario"],["dc.contributor.author","Cermak, Jaroslav"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Levis, Alessandro"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Maciejewski, Jaroslaw P."],["dc.contributor.author","Machherndl-Spandl, Sigrid"],["dc.contributor.author","Magalhaes, Silvia M. M."],["dc.contributor.author","Miyazaki, Yasushi"],["dc.contributor.author","Sekeres, Mikkael A."],["dc.contributor.author","Sperr, Wolfgang R."],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Tauro, Sudhir"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Vallespi, Teresa"],["dc.contributor.author","van de Loosdrecht, Arjan A."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Greenberg, Peter L."],["dc.date.accessioned","2018-11-07T10:10:07Z"],["dc.date.available","2018-11-07T10:10:07Z"],["dc.date.issued","2016"],["dc.description.abstract","In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower-and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making."],["dc.description.sponsorship","MDS Foundation, Inc."],["dc.identifier.doi","10.1182/blood-2016-02-700054"],["dc.identifier.isi","000383834800008"],["dc.identifier.pmid","27335276"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39793"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.relation.issn","1528-0020"],["dc.relation.issn","0006-4971"],["dc.title","Time-dependent changes in mortality and transformation risk in MDS"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","73483"],["dc.bibliographiccitation.issue","43"],["dc.bibliographiccitation.journal","Oncotarget"],["dc.bibliographiccitation.lastpage","73500"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Orazi, Attilio"],["dc.contributor.author","Steensma, David P."],["dc.contributor.author","Ebert, Benjamin L."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Malcovati, Luca"],["dc.contributor.author","van de Loosdrecht, Arjan A."],["dc.contributor.author","Haferlach, Torsten"],["dc.contributor.author","Westers, Theresia M."],["dc.contributor.author","Wells, Denise A."],["dc.contributor.author","Giagounidis, Aristoteles"],["dc.contributor.author","Loken, Michael"],["dc.contributor.author","Orfao, Alberto"],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Ogata, Kiyoyuki"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Béné, Marie C."],["dc.contributor.author","Hoermann, Gregor"],["dc.contributor.author","Sperr, Wolfgang R."],["dc.contributor.author","Sotlar, Karl"],["dc.contributor.author","Bettelheim, Peter"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Pfeilstöcker, Michael"],["dc.contributor.author","Horny, Hans-Peter"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Greenberg, Peter"],["dc.contributor.author","Bennett, John M."],["dc.date.accessioned","2019-12-17T12:21:04Z"],["dc.date.accessioned","2021-10-27T13:21:59Z"],["dc.date.available","2019-12-17T12:21:04Z"],["dc.date.available","2021-10-27T13:21:59Z"],["dc.date.issued","2017"],["dc.description.abstract","Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by peripheral cytopenia, dysplasia, and a variable clinical course with about 30% risk to transform to secondary acute myeloid leukemia (AML). In the past 15 years, diagnostic evaluations, prognostication, and treatment of MDS have improved substantially. However, with the discovery of molecular markers and advent of novel targeted therapies, new challenges have emerged in the complex field of MDS. For example, MDS-related molecular lesions may be detectable in healthy individuals and increase in prevalence with age. Other patients exhibit persistent cytopenia of unknown etiology without dysplasia. Although these conditions are potential pre-phases of MDS they may also transform into other bone marrow neoplasms. Recently identified molecular, cytogenetic, and flow-based parameters may add in the delineation and prognostication of these conditions. However, no generally accepted integrated classification and no related criteria are as yet available. In an attempt to address this challenge, an international consensus group discussed these issues in a working conference in July 2016. The outcomes of this conference are summarized in the present article which includes criteria and a proposal for the classification of pre-MDS conditions as well as updated minimal diagnostic criteria of MDS. Moreover, we propose diagnostic standards to delineate between ´normal´, pre-MDS, and MDS. These standards and criteria should facilitate diagnostic and prognostic evaluations in clinical studies as well as in clinical practice."],["dc.identifier.doi","10.18632/oncotarget.19008"],["dc.identifier.eissn","1949-2553"],["dc.identifier.pmid","29088721"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17006"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92060"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","1949-2553"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/3.0"],["dc.subject.ddc","610"],["dc.title","Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","Mallo, Mar"],["dc.contributor.author","Cervera, Jose"],["dc.contributor.author","Luno, Elisa"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Steidl, Christian"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Noesslinger, Thomas"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Krieger, Otto"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Schanz, Julie"],["dc.date.accessioned","2018-11-07T08:36:47Z"],["dc.date.available","2018-11-07T08:36:47Z"],["dc.date.issued","2010"],["dc.format.extent","1634"],["dc.identifier.isi","000289662204428"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18389"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","52nd Annual Meeting of the American-Society-of-Hematology (ASH)"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","0006-4971"],["dc.title","Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","23"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","126"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Tuechler, Heinz"],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","Sanz, Guillermo F."],["dc.contributor.author","Garcia-Manero, Guillermo"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Fenaux, Pierre"],["dc.contributor.author","Malcovati, Luca"],["dc.contributor.author","Cazzola, Mario"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Ohyashiki, Kazuma"],["dc.contributor.author","Levis, Alessandro"],["dc.contributor.author","Sekeres, Mikkael A."],["dc.contributor.author","Tauro, Sudhir"],["dc.contributor.author","Magalhaes, Silvia M. M."],["dc.contributor.author","van de Loosdrecht, Arjan A."],["dc.contributor.author","Cermak, Jaroslav"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Hellstrom-Lindberg, Eva"],["dc.contributor.author","Gindina, Tatjana"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:47:48Z"],["dc.date.available","2018-11-07T09:47:48Z"],["dc.date.issued","2015"],["dc.identifier.isi","000368020103074"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35176"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","57th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","1528-0020"],["dc.relation.issn","0006-4971"],["dc.title","Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","205"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Haematologica"],["dc.bibliographiccitation.lastpage","213"],["dc.bibliographiccitation.volume","100"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Müller-Thomas, Catharina"],["dc.contributor.author","Götze, Katharina"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Brümmendorf, Tim H."],["dc.contributor.author","Nolte, Florian"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Solé, Francesc"],["dc.contributor.author","Mallo, Mar"],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Ohyashiki, Kazuma"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Tüchler, Heinz"],["dc.contributor.author","Pfeilstöcker, Michael"],["dc.contributor.author","Nösslinger, Thomas"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Sperr, Wolfgang R."],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Schanz, Julie"],["dc.date.accessioned","2019-07-09T11:41:10Z"],["dc.date.available","2019-07-09T11:41:10Z"],["dc.date.issued","2015-02-01"],["dc.description.abstract","International Prognostic Scoring Systems are used to determine the individual risk profile of myelodysplastic syndrome patients. For the assessment of International Prognostic Scoring Systems, an adequate chromosome banding analysis of the bone marrow is essential. Cytogenetic information is not available for a substantial number of patients (5%-20%) with dry marrow or an insufficient number of metaphase cells. For these patients, a valid risk classification is impossible. In the study presented here, the International Prognostic Scoring Systems were validated based on fluorescence in situ hybridization analyses using extended probe panels applied to cluster of differentiation 34 positive (CD34(+)) peripheral blood cells of 328 MDS patients of our prospective multicenter German diagnostic study and compared to chromosome banding results of 2902 previously published patients with myelodysplastic syndromes. For cytogenetic risk classification by fluorescence in situ hybridization analyses of CD34(+) peripheral blood cells, the groups differed significantly for overall and leukemia-free survival by uni- and multivariate analyses without discrepancies between treated and untreated patients. Including cytogenetic data of fluorescence in situ hybridization analyses of peripheral CD34(+) blood cells (instead of bone marrow banding analysis) into the complete International Prognostic Scoring System assessment, the prognostic risk groups separated significantly for overall and leukemia-free survival. Our data show that a reliable stratification to the risk groups of the International Prognostic Scoring Systems is possible from peripheral blood in patients with missing chromosome banding analysis by using a comprehensive probe panel (clinicaltrials.gov identifier:01355913)."],["dc.identifier.doi","10.3324/haematol.2014.110452"],["dc.identifier.pmid","25344522"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11765"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58365"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1592-8721"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2096"],["dc.bibliographiccitation.issue","16"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","2097"],["dc.bibliographiccitation.volume","128"],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Tuechler, Heinz"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Sanz, Guillermo F."],["dc.contributor.author","Garcia-Manero, Guillermo"],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Bowen, David"],["dc.contributor.author","Fenaux, Pierre"],["dc.contributor.author","Dreyfus, Francois"],["dc.contributor.author","Kantarjian, Hagop M."],["dc.contributor.author","Kuendgen, Andrea"],["dc.contributor.author","Levis, Alessandro"],["dc.contributor.author","Malcovati, Luca"],["dc.contributor.author","Cazzola, Mario"],["dc.contributor.author","Cermak, Jaroslav"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Krieger, Otto"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Maciejewski, Jaroslaw P."],["dc.contributor.author","Magalhaes, Silvia M. M."],["dc.contributor.author","Miyazaki, Yasushi"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Sekeres, Mikkael A."],["dc.contributor.author","Sperr, Wolfgang R."],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Tauro, Sudhir"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Vallespi, Teresa"],["dc.contributor.author","van de Loosdrecht, Arjan A."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T10:06:55Z"],["dc.date.available","2018-11-07T10:06:55Z"],["dc.date.issued","2016"],["dc.description.sponsorship","NCI NIH HHS [P30 CA016672]"],["dc.identifier.doi","10.1182/blood-2016-07-728766"],["dc.identifier.isi","000385739900016"],["dc.identifier.pmid","27535995"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39189"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.relation.issn","1528-0020"],["dc.relation.issn","0006-4971"],["dc.title","Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1935"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Haematologica"],["dc.bibliographiccitation.lastpage","1949"],["dc.bibliographiccitation.volume","104"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Orazi, Attilio"],["dc.contributor.author","Savona, Michael R."],["dc.contributor.author","Patnaik, Mrinal M."],["dc.contributor.author","Onida, Francesco"],["dc.contributor.author","van de Loosdrecht, Arjan A."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Haferlach, Torsten"],["dc.contributor.author","Elena, Chiara"],["dc.contributor.author","Pleyer, Lisa"],["dc.contributor.author","Kern, Wolfgang"],["dc.contributor.author","Pemovska, Tea"],["dc.contributor.author","Vladimer, Gregory I."],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Keller, Alexandra"],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Lion, Thomas"],["dc.contributor.author","Sotlar, Karl"],["dc.contributor.author","Reiter, Andreas"],["dc.contributor.author","De Witte, Theo"],["dc.contributor.author","Pfeilstöcker, Michael"],["dc.contributor.author","Geissler, Klaus"],["dc.contributor.author","Padron, Eric"],["dc.contributor.author","Deininger, Michael"],["dc.contributor.author","Orfao, Alberto"],["dc.contributor.author","Horny, Hans-Peter"],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Arber, Daniel A."],["dc.contributor.author","Malcovati, Luca"],["dc.contributor.author","Bennett, John M."],["dc.date.accessioned","2020-12-10T18:44:19Z"],["dc.date.available","2020-12-10T18:44:19Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.3324/haematol.2019.222059"],["dc.identifier.eissn","1592-8721"],["dc.identifier.issn","0390-6078"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78404"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","809"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Genes Chromosomes and Cancer"],["dc.bibliographiccitation.lastpage","817"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Mueller-Thomas, Catharina"],["dc.contributor.author","Goetze, Katharina S."],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Ohyashiki, Kazuma"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Tuechler, Heinz"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Schanz, Julie"],["dc.date.accessioned","2018-11-07T09:48:36Z"],["dc.date.available","2018-11-07T09:48:36Z"],["dc.date.issued","2015"],["dc.description.abstract","In myelodysplastic syndromes (MDS), deletion of the short arm of chromosome 12 (del(12p)) is usually a small abnormality, rarely detected as a single aberration by chromosome banding analysis (CBA) of bone marrow metaphases. Del(12p) has been described in 0.6 to 5% of MDS patients at initial diagnosis and is associated with a good to intermediate prognosis as a sole anomaly according to current scoring systems. Here, we present the results of a systematic del(12p) testing in a German prospective diagnostic study (clinicaltrials.gov: NCT01355913) on 367 MDS patients in whom CD34+ peripheral blood cells were analysed for the presence of del(12p) by sequential fluorescence in situ hybridization (FISH) analyses. A cohort of 2,902 previously published MDS patients diagnosed by CBA served as control. We demonstrate that, using a sensitive FISH technique, 12p deletion occurs significantly more frequently in MDS than previously described (7.6% by CD34+ PB-FISH vs. 1.6% by CBA, P < 0.001) and is often associated with other aberrations (93% by CD34+ PB-FISH vs. 60% by CBA). Additionally, the detection rate can be increased by repeated analyses in a patient over time which is important for the patients prognosis to distinguish a sole anomaly from double or complex aberrations. To our knowledge, this is the first study to screen for 12p deletions with a suitable probe for ETV6/TEL in 12p13. Our data suggest that the supplement of a probe for the detection of a 12p deletion to common FISH probe panels helps to avoid missing a del(12p), especially as part of more complex aberrations. (C) 2015 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/gcc.22292"],["dc.identifier.isi","000365405700010"],["dc.identifier.pmid","26355708"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35339"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1098-2264"],["dc.relation.issn","1045-2257"],["dc.title","Frequency of del(12p) is Commonly Underestimated in Myelodysplastic Syndromes: Results from a German Diagnostic Study in Comparison with an International Control Group"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Stephanie, Fischer"],["dc.contributor.author","Haferlach, Claudia"],["dc.contributor.author","Bardi, Georgia"],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Eclache, Virginie"],["dc.contributor.author","Johansson, Bertil"],["dc.contributor.author","Ohyashiki, Kazuma"],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","Prescher, Gabriele"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Noesslinger, Thomas"],["dc.contributor.author","Fonatsth, Christa"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Wimzal, Friedrich"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Krieger, Otto"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T08:36:47Z"],["dc.date.available","2018-11-07T08:36:47Z"],["dc.date.issued","2010"],["dc.format.extent","1639"],["dc.identifier.isi","000289662204442"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18391"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","52nd Annual Meeting of the American-Society-of-Hematology (ASH)"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","0006-4971"],["dc.title","Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia Characterization and Prognostic Relevance"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]